Senior Director, EUCAN regulatory affairs GI and Inflammation TA head. 

Lada Leyens has a background in human genetics, health economics and personalised medicine. She has worked at Health Authorities for over 8 years, mainly in the approval of clinical trials and as a GCP inspector at Swissmedic. At EMA she was in the specialised disciplines office working in the centralised procedure and with the Pharmacokinetic and Pharmacogenomic Working Parties. At Roche, Lada was Regulatory Lead for digital health programs and the Regulatory Shaping Lead on Clinical Trial Innovation. At Takeda, she leads the EUCAN regulatory team in the therapeutic area of GI and Inflammation. Lada is vice-chair of EFPIA-CREG and represents EFPIA and industry at multistakeholder platforms, such as the ACT-EU Multistakeholder Platform Advisory Group.  She is passionate about leveraging innovative technologies to make drug development more efficient and bringing innovative drugs to patients faster.